Research theme for competitive and other funds (3)：
2013 - 2016 Where and how are mature platelets produced?
1998 - 2002 白血病の微少残存病変の定量
1998 - 2002 The quantitation of minimal residual disease in acute leukemia
Papers (91)：
Tatsuo Oyake, Takahiro Maeta, Takenori Takahata, Yoshiko Tamai, Yoshihiro Kameoka, Naoto Takahashi, Yasuro Miyairi, Kazunori Murai, Kenji Shimosegawa, Kozue Yoshida, et al. Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma. Journal of clinical and experimental hematopathology : JCEH. 2024
Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Hiroshi Handa, Yasushi Hiramatsu, Taiga Kuroi, Kazuki Tanimoto, Kosei Matsue, Masahiro Abe, et al. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan. Annals of hematology. 2023
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki, Hiroshi Handa, Takaaki Chou, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki, et al. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma. Annals of hematology. 2023. 102. 9. 2493-2504
Yu Abe, Makoto Sasaki, Naoki Takezako, Shigeki Ito, Kazuhito Suzuki, Hiroshi Handa, Takaaki Chou, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki, et al. Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi-based therapy in relapsed/refractory multiple myeloma. Annals of hematology. 2023. 102. 9. 2505-2505
Shugo Kowata, Yuki Seki, Yasuhiko Tsukushi, Tsuyoshi Sato, Kazuya Asano, Takahiro Maeta, Akiko Yashima-Abo, Ryosei Sasaki, Yoshiaki Okano, Tatsuo Oyake, et al. Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma. International journal of hematology. 2023
Mariko Ishibashi, Ryosuke Kinoshita, Koiti Inokuchi, Hiroshi Handa, Makoto Sasaki, Norio Komatsu, Yoichi Imai, Norina Hiroike, Junji Tanaka, Sakae Tanosaki, et al. Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. BLOOD. 2019. 134
Akio Saito, Atsushi Isoda, Takeshi Odajima, Mitsuhiro Itagaki, Go Yamamoto, Shotaro Hagiwara, Tatsuharu Ohno, Ayumi Fujimoto, Naohiro Sekiguchi, Kazutaka Sunami, et al. A New Prognostic Index for Waldenstrom Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma. BLOOD. 2018. 132
